Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine.
BACKGROUND
Most patients with major depressive disorder (MDD) experience a period of lengthy trial and error when trying to find optimal antidepressant treatment; identifying biomarkers that could predict response to antidepressant treatment would be of enormous benefit. We tested the hypothesis that pretreatment anterior cingulate cortex (ACC) activity could be a putative biomarker of rapid antidepressant response to ketamine, in line with previous findings that investigated the effects of conventional antidepressants. We also investigated patterns of ACC activity to rapid presentation of fearful faces compared with the normal habituation observed in healthy subjects.


METHODS
We elicited ACC activity in drug-free patients with MDD (n = 11) and healthy control subjects (n = 11) by rapidly presenting fearful faces, a paradigm known to activate rostral regions of the ACC. Spatial-filtering analyses were performed on magnetoencephalographic (MEG) recordings, which offer the temporal precision necessary to estimate ACC activity elicited by the rapid presentation of stimuli. Magnetoencephalographic recordings were obtained only once for both patients and control subjects. Patients were subsequently administered a single ketamine infusion followed by assessment of depressive symptoms 4 hours later.


RESULTS
Although healthy subjects had decreased neuromagnetic activity in the rostral ACC across repeated exposures, patients with MDD showed robust increases in pretreatment ACC activity. Notably, this increase was positively correlated with subsequent rapid antidepressant response to ketamine. Exploratory analyses showed that pretreatment amygdala activity was negatively correlated with change in depressive symptoms.


CONCLUSIONS
Pretreatment rostral ACC activation may be a useful biomarker that identifies a subgroup of patients who will respond favorably to ketamine's antidepressant effects.
Salvadore
Giacomo
G
Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA.
Cornwell
Brian R
BR
Colon-Rosario
Veronica
V
Coppola
Richard
R
Grillon
Christian
C
Zarate
Carlos A
CA
Manji
Husseini K
HK
D000328:Adult; D000679:Amygdala / Q000502:physiology; D000928:Antidepressive Agents / Q000627:therapeutic use*; D015415:Biomarkers; D002540:Cerebral Cortex / Q000502:physiology*; D003627:Data Interpretation, Statistical; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000523:psychology*; D005149:Facial Expression; D005239:Fear / Q000502:physiology*; D005260:Female; D006179:Gyrus Cinguli / Q000502:physiology*; D006801:Humans; D007649:Ketamine / Q000627:therapeutic use*; D015225:Magnetoencephalography; D008297:Male; D008875:Middle Aged; D010775:Photic Stimulation; D011237:Predictive Value of Tests; D011569:Psychiatric Status Rating Scales
D000928:Antidepressive Agents; D015415:Biomarkers; D007649:Ketamine